- Home
- ANDG vs TARS Comparison
ANDG vs TARS Comparison
Compare ANDG & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANDG | TARS |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANDG | TARS |
|---|---|---|
| Price | $23.20 | $71.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $29.50 | ★ $76.56 |
| AVG Volume (30 Days) | 428.4K | ★ 709.0K |
| Earning Date | 01-01-0001 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $810,756,000.00 | $366,100,000.00 |
| Revenue This Year | N/A | $147.34 |
| Revenue Next Year | N/A | $53.50 |
| P/E Ratio | $46.24 | ★ N/A |
| Revenue Growth | 26.86 | ★ 182.44 |
| 52 Week Low | $20.00 | $38.51 |
| 52 Week High | $27.51 | $85.25 |
Technical Indicators
Market Signals| Indicator | ANDG | TARS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 26.51 |
| Support Level | N/A | $76.91 |
| Resistance Level | N/A | $76.22 |
| Average True Range (ATR) | 0.00 | 3.15 |
| MACD | 0.00 | -1.09 |
| Stochastic Oscillator | 0.00 | 0.12 |
Price Performance
Historical ComparisonAbout ANDG Andersen Group Inc. Class A Common Stock
Andersen Group Inc is a provider of independent tax, valuation and financial advisory services to individuals and family offices, businesses and institutional clients in the United States. It has strategically expanded its business to build an integrated platform of service offerings that enables the company to solve its clients' complex tax and financial challenges. The company's end-to-end services offerings include: Private Client Services, Business Tax Services, Alternative Investment Funds, and Valuation Services.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.